Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Mar 10, 2026
- Pharmaceuticals
- R&D
Roche’s Announcement Regarding giredestrant (Announcement of Phase III persevERA Study Results)
TOKYO, March 10, 2026 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a media release on March 9, regarding the results of the global Phase III clinical trial (persevERA) evaluating giredestrant in estrogen receptor (ER)-positive locally advanced or metastatic breast cancer.
The detailed data will be presented at an upcoming medical meeting.
Please refer to the link below for details of the media release:
Roche provides update on phase III persevERA study in ER-positive advanced breast cancer
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Naoki Kozai
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp